Last reviewed · How we verify
NCT07425574: EVOLVE
A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
trial testing No Intervention in Stargardt Disease in 90 participants. Currently enrolling.
31 July 2028
Quick facts
| Lead sponsor | Astellas Pharma Global Development, Inc. |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 20 February 2026 |
| Primary completion | 31 July 2028 |
| Estimated completion | 31 July 2028 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- No Intervention
Conditions studied
- Stargardt Disease — all drugs for Stargardt Disease →
- Stargardt Macular Dystrophy — all drugs for Stargardt Macular Dystrophy →
- Stargardt-like Macular Dystrophy — all drugs for Stargardt-like Macular Dystrophy →
Sponsor
Astellas Pharma Global Development, Inc. — full company profile →
Who can join
6 and older, any sex, with Stargardt Disease or Stargardt Macular Dystrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In people with macular dystrophies, some of the cells in the macula gradually stop working and may die over time. This leads to vision loss in the center of the eye. Side vision (peripheral vision) is mostly unaffected. Stargardt disease (STGD) is a type of macular dystrophy which is caused by 1 faulty gene (ABCA4). Vision loss most typically happens in childhood, but many people do not develop it until they are adults. As well as STGD, there are other macular dystrophies that look very similar to STGD but that are caused by many other different genes. Together, STGD and STGD-like conditions can be called STGD-type macular dystrophies. This is because they look the same clinically and have similar symptoms. Since different genes can cause these conditions, genetic testing is the only way to be sure which specific condition a person has. In this study, researchers want to learn if the disease progresses in a similar way in people with STGD and STGD-like macular dystrophies. People taking part in the study will continue to manage their condition, as agreed with their own doctor. People will visit their clinic every 6 months to have various standard eye tests and imaging. The information collected will include questions about people's wellbeing, general health, medication and supplements taken, and daily activities. Children over 6 years old and adults with STGD-type macular dystrophies may take part in this study. They will be in the study for up to 24 months (2 years). The study sponsor (Astellas) will not decide how people's condition is managed. However, the sponsor will provide instructions on when people visit their clinic and what is recorded during the study. If available, medical records, clinical and imaging data from previous visits going back 24 months will also be reviewed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07425574
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No Intervention
Trials testing the same drug.
- NCT07353099 — A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma · not yet recruiting
- NCT07429942 — A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Recei · not yet recruiting
- NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
- NCT07319832 — A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome · recruiting
- NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
Other recruiting trials for Stargardt Disease
Currently open trials in the same condition.
- NCT07266584 — Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration · NA · recruiting
- NCT07439887 — Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients · Phase 1, PHASE2 · recruiting
- NCT07417566 — A Study of DC6001 Tablet in Healthy Chinese Adult Subjects · Phase 1 · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06942572 — A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficac · Phase 1, PHASE2 · recruiting
Other Astellas Pharma Global Development, Inc. trials
Trials by the same sponsor.
- NCT07488676 — A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07475806 — A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep · Phase 2 · recruiting
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07287995 — A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07395024 — A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07425574 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Global Development, Inc.
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07425574.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing